Suppr超能文献

HIV-1 成熟抑制剂结合口袋的结构与功能见解。

Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.

机构信息

Virus-Cell Interaction Section, HIV Drug Resistance Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America.

出版信息

PLoS Pathog. 2012;8(11):e1002997. doi: 10.1371/journal.ppat.1002997. Epub 2012 Nov 8.

Abstract

Processing of the Gag precursor protein by the viral protease during particle release triggers virion maturation, an essential step in the virus replication cycle. The first-in-class HIV-1 maturation inhibitor dimethylsuccinyl betulinic acid [PA-457 or bevirimat (BVM)] blocks HIV-1 maturation by inhibiting the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate to mature CA. A structurally distinct molecule, PF-46396, was recently reported to have a similar mode of action to that of BVM. Because of the structural dissimilarity between BVM and PF-46396, we hypothesized that the two compounds might interact differentially with the putative maturation inhibitor-binding pocket in Gag. To test this hypothesis, PF-46396 resistance was selected for in vitro. Resistance mutations were identified in three regions of Gag: around the CA-SP1 cleavage site where BVM resistance maps, at CA amino acid 201, and in the CA major homology region (MHR). The MHR mutants are profoundly PF-46396-dependent in Gag assembly and release and virus replication. The severe defect exhibited by the inhibitor-dependent MHR mutants in the absence of the compound is also corrected by a second-site compensatory change far downstream in SP1, suggesting structural and functional cross-talk between the HIV-1 CA MHR and SP1. When PF-46396 and BVM were both present in infected cells they exhibited mutually antagonistic behavior. Together, these results identify Gag residues that line the maturation inhibitor-binding pocket and suggest that BVM and PF-46396 interact differentially with this putative pocket. These findings provide novel insights into the structure-function relationship between the CA MHR and SP1, two domains of Gag that are critical to both assembly and maturation. The highly conserved nature of the MHR across all orthoretroviridae suggests that these findings will be broadly relevant to retroviral assembly. Finally, the results presented here provide a framework for increased structural understanding of HIV-1 maturation inhibitor activity.

摘要

在颗粒释放过程中,病毒蛋白酶对 Gag 前体蛋白的加工触发病毒粒子成熟,这是病毒复制周期中的一个关键步骤。首个 HIV-1 成熟抑制剂二甲基琥珀酰桦木酸[PA-457 或贝维莫特(BVM)]通过抑制衣壳-间隔肽 1(CA-SP1)中间体的裂解来阻止 HIV-1 成熟,从而成熟 CA。最近报道了一种结构不同的分子 PF-46396,其作用模式与 BVM 相似。由于 BVM 和 PF-46396 之间的结构差异,我们假设这两种化合物可能以不同的方式与 Gag 中假定的成熟抑制剂结合口袋相互作用。为了验证这一假设,我们在体外选择了对 PF-46396 的抗性。在 Gag 的三个区域中鉴定出了耐药突变:在 CA-SP1 切割位点附近,BVM 耐药区域,在 CA 氨基酸 201 处,以及在 CA 主要同源区(MHR)。在 Gag 组装和释放以及病毒复制过程中,MHR 突变体对 PF-46396 高度依赖。在没有化合物的情况下,抑制剂依赖性 MHR 突变体表现出严重缺陷,而在 SP1 中远距离的第二个补偿性变化也可以纠正这种缺陷,这表明 HIV-1 CA MHR 和 SP1 之间存在结构和功能的交叉对话。当 PF-46396 和 BVM 都存在于感染细胞中时,它们表现出相互拮抗的行为。总之,这些结果确定了 Gag 残基,这些残基构成了成熟抑制剂结合口袋,并表明 BVM 和 PF-46396 以不同的方式与这个假定的口袋相互作用。这些发现为 CA MHR 和 SP1 之间的结构-功能关系提供了新的见解,这两个结构域对于组装和成熟都至关重要。MHR 在所有正逆转录病毒科中的高度保守性表明,这些发现将广泛适用于逆转录病毒的组装。最后,这里呈现的结果为提高对 HIV-1 成熟抑制剂活性的结构理解提供了一个框架。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d970/3493477/b530b477e814/ppat.1002997.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验